- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update
Krystal Biotech (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for dermatological diseases, today reports financial results for the first quarter ended March 31, 2018, and provides an update on the company’s recent corporate progress. As quoted in the press release: “To date, 2018 has been marked by significant progress for Krystal Biotech, …
Krystal Biotech (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for dermatological diseases, today reports financial results for the first quarter ended March 31, 2018, and provides an update on the company’s recent corporate progress.
As quoted in the press release:
“To date, 2018 has been marked by significant progress for Krystal Biotech, including clearance of the KB103 IND by the FDA for the treatment of dystrophic epidermolysis bullosa (DEB), granting of the U.S. composition of matter patent covering HSV vectors and methods of using the same to treat skin diseases, and the Company receiving Orphan Medicinal Product Designation in Europe for KB103,” said Krish S. Krishnan, chief executive officer of Krystal Biotech. “As we continue this momentum in 2018, we look forward to announcing clinical results on KB103, filing the Investigational New Drug (IND) application on KB105 for the treatment of lamellar ichthyosis, and getting our Good Manufacturing Practice (GMP) facility ready for manufacturing our pipeline products.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.